Glaucoma – Unmet Need – Detailed, Expanded Analysis (US/EU)
Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States and Europe. The majority of glaucoma patients have primary open-angle glaucoma (POAG). Treatment of POAG aims to lower and stabilize IOP; pharmacotherapy is widely used for this purpose. The pharmaceutical market for POAG is broad and highly genericized. Prostaglandin analogues, such as latanoprost and bimatoprost are the long-standing first-class treatment option for POAG due to their demonstrated efficacy, safety, and once-per-day self-administration. Beta blockers such as timolol are widely used as follow-up therapies; other later-line agents include alpha agonists and carbonic anhydrase inhibitors. In 2018, Alcon’s (formerly Aerie’s) first-in-class Rhopressa (netarsudil) received FDA approval, followed in 2019 by its netarsudil / latanoprost FDC, Rocklatan; both agents have since received EMA approval in Europe. The current POAG pipeline is active and includes novel agents as well as alternative formulations of existing therapies with differing administration requirements. By examining the key treatment drivers and greatest areas of unmet need in POAG prescribing, this content presents the opportunities in this space.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for POAG?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for POAG?
- What are the prevailing areas of unmet need and opportunity in POAG?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new POAG drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European ophthalmologists fielded in July 2023
Key companies: AbbVie / Allergan, Pfizer, Novartis, Merck & Co, Viatris, Théa
Key drugs: Xalatan, Lumigan, timolol, Alphagan, Azopt, Combigan, Cosopt
Table of contents
- Glaucoma - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Unmet Need - POAG - TPP Simulator - September 2023
- Executive Summary
- Introduction
- Treatment Drivers and Goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed ophthalmologists' prescribing decisions in POAG
- Importance of efficacy attributes to prescribing decisions in POAG: United States
- Importance of efficacy attributes to prescribing decisions in POAG: Europe
- Importance of safety and tolerability attributes to prescribing decisions in POAG: United States
- Importance of safety and tolerability attributes to prescribing decisions in POAG: Europe
- Importance of convenience of administration attributes to prescribing decisions in POAG: United States
- Importance of convenience of administration attributes to prescribing decisions in POAG: Europe
- Importance of nonclinical factors to prescribing decisions in POAG: United States
- Importance of nonclinical factors to prescribing decisions in POAG: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in POAG: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in POAG: Europe
- Product Performance Against Treatment Drivers and Goals
- Key findings
- Overall performance of key therapies for POAG: United States
- Overall performance of key therapies for POAG: Europe
- Mean overall performance of key therapies for POAG: United States and Europe
- Relative performance of key therapies for POAG across select efficacy attributes: United States
- Relative performance of key therapies for POAG across select efficacy attributes: Europe
- Relative performance of key therapies for POAG across select safety and tolerability attributes: United States
- Relative performance of key therapies for POAG across select safety and tolerability attributes: Europe
- Relative performance of key therapies for POAG across select convenience of administration attributes: United States
- Relative performance of key therapies for POAG across select convenience of administration attributes: Europe
- Relative performance of key therapies for POAG across select nonclinical attributes: United States
- Relative performance of key therapies for POAG across select nonclinical attributes: Europe
- Assessment of Unmet Need
- Key findings: unmet need in POAG
- Surveyed ophthalmologistsu2019 satisfaction with the performance of key therapies for POAG on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed ophthalmologistsu2019 satisfaction with the performance of key therapies for POAG on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key efficacy attributes in POAG: United States
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key efficacy attributes in POAG: Europe
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in POAG: United States
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in POAG: Europe
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key convenience of administration attributes in POAG: United States
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key convenience of administration attributes in POAG: Europe
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key nonclinical factors in POAG: United States
- Surveyed ophthalmologistsu2019 ascribed level of unmet need across key nonclinical factors in POAG: Europe
- Key findings: unmet need in POAG and related indications
- Surveyed ophthalmologists' ascribed level of unmet need in POAG and related indications: United States
- Surveyed ophthalmologistsu2019 ascribed level of unmet need in POAG and related indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
Matthew D. Litke, M.S., :ead Healthcare Research & Data Analyst, CNS and Ophthalmology. Mr. Litke supports Clarivate’s Treatment Algorithms Claims Data Analysis report series, in addition to authoring syndicated content in the CNS and ophthalmology therapy areas. He holds a B.S. in biochemistry and molecular biology from Penn State University and an M.S. in psychology from Villanova University.